Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Company Update

9 Jul 2013 14:00

RNS Number : 9025I
Ark Therapeutics Group PLC
09 July 2013
 



Ark Therapeutics Group plc

 

Company Update

 

London, UK, 9 July 2013 - Ark Therapeutics Group plc (LSE: AKT) ("Ark") confirms that the contract with Crawford Healthcare relating to the sale of the Woundcare Business sold to Crawford Healthcare in 2011 has been terminated and in return for an immediate payment of £300,000 Ark has agreed to release Crawford Healthcare from any future obligations under the contract.

 

David Venables, Non-Executive Director commented: "We have reached an amicable agreement which benefits both parties."

 

 

For further information please contact:

 

Ark Therapeutics Group plc

Tel: +44 (0)207 002 1005 

 

Iain G Ross, Non-Executive Chairman

 

David Venables, Non-Executive Director

 

 

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding Ark's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond Ark's control that could cause the actual results, performance or achievements of Ark to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Ark's present and future business strategies and the environment in which Ark will operate in the future. These forward-looking statements speak only as at the date of this announcement. Ark expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in Ark's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFVADVIAIIV
Date   Source Headline
21st Mar 20054:29 pmRNSDirector Shareholding
21st Mar 20054:21 pmRNSDirector Shareholding
14th Mar 20055:55 pmRNSDirector's Share Dealing
14th Mar 20055:06 pmRNSDirector Shareholding
14th Mar 20055:00 pmRNSDirector Shareholding
10th Mar 20057:01 amRNSFinal Results
21st Jan 20057:00 amRNSGranted Patent
19th Jan 20054:21 pmRNSInterest in Shares
17th Jan 20057:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.